KIF1C: A Non-Protein Kinase Inhibitor as A Potential Drug Target and Biomarker

Target Name: KIF1C

NCBI ID: G10749

KIF1C

KIF1C: A Non-Protein Kinase Inhibitor as A Potential Drug Target and Biomarker

KIF1C, also known as KIF1C gene, is a gene that encodes a protein known as KIF1C. KIF1C is a non-protein kinase inhibitor 1C (NPI1C), which is a type of protein that is expressed in various tissues throughout the body. NPI1C plays a crucial role in cell signaling, particularly in the regulation of cell adhesion, migration, and invasion.

Recent studies have identified KIF1C as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. The potential of KIF1C as a drug target is based on its unique mechanism of action and its expressed role in various cellular processes that are associated with the development and progression of these diseases.

One of the key reasons for the potential of KIF1C as a drug target is its unique mechanism of action. KIF1C is a non-protein kinase inhibitor, which means that it inhibits the activity of protein kinases. These enzymes are involved in various cellular processes, including cell signaling, DNA replication, and cell division. By inhibiting the activity of protein kinases, KIF1C can disrupt the regulation of cellular processes that are associated with the development and progression of diseases.

In addition to its unique mechanism of action, KIF1C is also expressed in various tissues throughout the body, which makes it an attractive target for drugs that can cross-species. This is important because it allows researchers to study the effects of drugs on KIF1C expression and function in different organisms, which can provide valuable insights into the potential implications of KIF1C as a drug target.

Recent studies have also identified KIF1C as a potential biomarker for various diseases. The expression of KIF1C has been observed in various tissues and fluids, including blood, saliva, urine, and tissue samples from cancer patients. Additionally, KIF1C has been shown to be involved in the regulation of cellular processes that are associated with the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Another promising aspect of KIF1C as a drug target is its potential to target multiple diseases. Its unique mechanism of action and its expressed role in various cellular processes make it an attractive target for drugs that can be used to treat a wide range of diseases. For example, KIF1C has been shown to be involved in the regulation of cellular processes that are associated with the development and progression of cancer, neurodegenerative diseases, and autoimmune disorders.

In conclusion, KIF1C is a gene that encodes a protein known as KIF1C. KIF1C is a non-protein kinase inhibitor 1C that plays a crucial role in cell signaling, particularly in the regulation of cell adhesion, migration, and invasion. Its unique mechanism of action and its expressed role in various cellular processes make it an attractive target for drugs that can be used to treat a wide range of diseases. Further research is needed to fully understand the potential implications of KIF1C as a drug target and biomarker.

Protein Name: Kinesin Family Member 1C

Functions: Motor required for the retrograde transport of Golgi vesicles to the endoplasmic reticulum. Has a microtubule plus end-directed motility

The "KIF1C Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about KIF1C comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets